Parkinson's Disease (PD) is characterized by the loss of dopaminergic neurons in the substantia 14 nigra resulting in severe motor impairments. However, the mechanisms underlying this neuronal 15 loss remain largely unknown. Activating Transcription Factor 4 (ATF4), a key mediator of the 16
Introduction 34
Parkinson's disease (PD) is the second most common neurodegenerative disorder and is 35 characterized by distinct motor symptoms including bradykinesia, postural rigidity and resting 36 tremor (Postuma et al., 2015) . The motor impairments in PD result from the progressive loss of 37 dopaminergic neurons in the substantia nigra pars compacta and the associated depletion of 38 striatal dopamine (Damier, Hirsch, Agid, & Graybiel, 1999) . A hallmark of PD is the appearance of 39 intracellular protein inclusions called Lewy Bodies in which aggregates of misfolded α-synuclein 40 are a major component (Spillantini et al., 1997) . Although the majority of PD cases are sporadic, 41 risk genes including PARK1 (α-synuclein), PARKIN, PINK1, DJ-1 and LRRK2, have been identified in 42 familial forms of the disease (reviewed by Zeng, Geng, Jia, Chen, & Zhang, 2018) . Unfortunately, 43
there is no cure for PD and while current treatments temporarily ameliorate some of the clinical 44 symptoms, they do not mitigate the underlying degenerative processes. 45 46 Numerous studies implicate oxidative stress and ER stress as major factors contributing to 47 dopaminergic neuronal cell death in PD. Indeed, markers of oxidative damage including DNA 48 damage, lipid peroxidation and aggregates of oxidized proteins have been reported in post-49 mortem brain tissue of PD patients (Baba et al., 1998; Bosco et al., 2006) . The role of oxidative 50 stress is also supported by the finding that environmental toxins (paraquat, rotenone) and 51 neurotoxic agents (MPTP, 6-OHDA) can inhibit mitochondrial function and increase the 52 production of reactive oxygen species cause loss of dopaminergic neurons in rodents, non-53 human primates and humans (Bove, Prou, Perier, & Przedborski, 2005) . Furthermore, several 54 familial-linked PD genes including Parkin, Pink1 and DJ-1 have been implicated in the regulation 55 of mitochondrial function, mitophagy and ROS production (Clark et al., 2006; Geisler et al., 2010; 56 Lee, Nagano, Taylor, Lim, & Yao, 2010; Narendra et al., 2010) . In addition to oxidative stress, 57 deficits in cellular proteostasis pathways associated with the accumulation and aggregation of 58 misfolded proteins such as α-synuclein is thought to contribute to neurodegeneration in PD 59 (Kaushik & Cuervo, 2015) . One component of the proteostasis network that is affected in PD is 60 the folding capacity of the endoplasmic reticulum (ER) resulting in ER stress and activation of the Therefore, in the present study we investigated the role of ATF4 in primary neurons exposed to 85 PD neurotoxins (MPP+ and 6-OHDA) and a-synuclein preformed fibrils. 86 a-synuclein preformed fibrils. Human a-synuclein monomers (Proteos #RP-003) were used to 115 generate fibrils based on protocol from Volpicelli-Daley, Luk, & Lee (2014). Briefly, monomers 116 were shaken at 1000 rpm (37˚C) for 7 days to obtained preformed fibrils, aliquoted and stored at 117 -80˚C. Aliquots were then thawed at room temperature immediately before use. PFFs were 118 diluted in warm medium and sonicated with a probe tip at 10% power for 30 seconds (0.5 119 seconds on, 0.5 seconds off). Sonicated fibrils were added to neuronal culture at a final 120 concentration of 5 µg/mL. (Figure 2A and 2B) . However, the increase in 217 expression of these pro-apoptotic factors in response to PD neurotoxins was largely attenuated 218 in ATF4-/-neurons. Taken together these results indicate that sustained activation of ATF4 is 219 required for transcriptional induction of key pro-apoptotic target genes by PD neurotoxins. 4A). Consistent with the apoptotic counts we also found that the level of cleaved (active) 247
Caspase-3 induced by MPP+ and 6-OHDA treatments was markedly reduced in ATF4-/-neurons 248 as compared to ATF4+/+ neurons ( Figure 4B and 4C ). Next to determine whether ATF4-deficient 249 neurons remained viable following treatment with PD-neurotoxins and were not just dying by a 250 non-apoptotic mode of cell death we assessed neuronal survival in ATF4 +/+ and ATF4 -/-using 251
Calcein-AM/ethidium homodimer staining (Live/Dead assay). As shown in Figure 4D , MPP+ and 252 6-OHDA treatment markedly reduced cell viability in ATF4+/+ neuronal, but not in ATF4-/-253 neuronal cultures indicating that ATF4-deficient neurons remain viable. 254
Dopaminergic neurons of the substantia nigra are the primary neuronal population of neurons 255 affected in PD. Therefore, we sought to determine whether ATF4 promotes cell death specifically 256 in dopaminergic neurons exposed to PD toxins. To address this question, we generated 257 mesencephalic cultures from the ventral midbrain region of ATF4+/+ and ATF4-/-mouse 258 embryos and subsequently exposed them to MPP+ or 6-OHDA. Only a small portion of the 259 neurons in these mesencephalic cultures are dopaminergic (DA) therefore In order to quantify 260 the extent of DA neuron loss in these models, we quantified the number of neurons with positive 261 is highly phosphorylated at Ser129 (Fujiwara et al., 2002) . Therefore, to validate this 278 synucleinopathy paradigm we treated cortical neurons with α-Syn PFFs and confirmed the 279 formation of phospho-Ser193-α-synuclein positive inclusions ( Figure 6A ). We then performed 280 ATF4 immunostaining to determine whether α-Syn PFF induced lesions resulted in the induction 281 of ATF4 expression. Indeed, as shown in Figure 6B , α-Syn PFF treated cultures exhibited a 282 significant increase in nuclear ATF4 staining as compared to untreated neurons. We next sought 283 to determined whether α-Syn PFF induced inclusions led to neuronal death, and if so whether 284 this was dependent upon ATF4 expression. To address this question, we treated cortical neurons 285 derived from ATF4+/+ and ATF4-/-mice with α-Syn PFFs and then assessed apoptosis by 286 examining nuclear morphology. As shown in Figure 6C , α-Syn PFF treatment caused a 287 significantly greater induction of apoptosis in ATF4+/+ neurons than in ATF4-/-neurons. Next, we 288 probed mesencephalic cultures treated with preformed a-synuclein fibrils to examine whether 289 loss of ATF4 affects pathogenic α-synuclein induced dopaminergic neuron death. Α-Syn PFF 290 induced synucleinopathy resulted in the loss of 81.65% of TH+ dopaminergic neurons in ATF4+/+ 291 cultures, but only a 41.85% reduction in dopaminergic neurons in ATF4-/-cultures ( Figure 6D) . 292
Taken together these results indicate that ATF4 is activated in response to pathogenic α-293 synuclein aggregation and promotes neuronal death. 294
295
The eIF2α kinase inhibitor C16 inhibits ATF4 activation and protects against neuronal death in 296 cellular models of PD 297 298 Oxidative stress and ER stress have been implicated in PD and are known to trigger the 299 Integrated Stress Response and subsequent induction of ATF4 through the activation of eIF2α 300 kinases. Given our findings that ATF4 is activated in PD models and promotes neuronal death we 301 reasoned that pharmacological inhibition of eIF2α kinases that contribute to ATF4 activation in 302 response to oxidative stress and ER stress may be neuroprotective in PD. In preliminary 303 experiments we found that the imidazole-oxindole PKR inhibitor commonly known as C16 was 304 able to inhibit ATF4 induction in neurons following treatment with the oxidative stressor arsenite 305 as well as the ER stress inducing agent thapsigargin (data not shown). Therefore, we tested the 306 effects of this eIF2α kinase inhibitor in cellular models of PD. We first investigated whether C16 307 could inhibit PD neurotoxin induced ATF4 activation. As shown in figure 7A , C16 administration 308 significantly reduced the levels of ATF4 induced by both MPP+ and 6-OHDA treatments. We next 309 investigated whether C16 could inhibit the induction of the ATF4-dependent pro-apoptotic 310 target genes Chop and Trib3. Consistent with the ability of C16 to inhibit ATF4 induction, we 311 found that the transcriptional induction of Chop and Trb3 mRNAs by MPP+ and 6-OHDA was 312 significantly attenuated in the presence of C16 ( Figure 7B) . Given that C16 decreased ATF4 313 protein and represses transcriptional activation of its downstream targets, we next evaluated 314 whether C16 is neuroprotective in PD neurotoxin paradigms. To test this, we treated cortical 315 neurons with MPP+ or 6-OHDA in the presence or absence of C16 and then assessed the level of 316 apoptotic cell death after 24 hours. As shown in Figure 7C, Parkinson's disease is characterized by the loss of dopaminergic neurons, leading to a reduction 327 of dopamine levels, which produce the cardinal motor symptoms of the disease. Currently, 328 treatments are directed towards dopamine replacement therapies, which provide some 329 symptomatic relief, however become less effective over time and do not attenuate the 330 progression of the disease. Unfortunately, the underlying mechanism of neurodegeneration in 331
Parkinson's disease remains poorly understood. In this study, we have demonstrated that ATF4 332 induction in cellular models of PD triggers neuronal cell death through transcriptional activation 333 of known pro-death genes and subsequent apoptotic processes. Specifically, we have 334 determined that (a) ATF4 expression is increased following neuronal injury caused by PD neurotoxins (MPP+ and 6-OHDA) as well as by α-synuclein aggregates produced by preformed a-336 synuclein fibrils, that (b) ATF4 is transcriptionally active and promotes the expression of the pro-337 apoptotic target genes Trib3, CHOP, and PUMA, that (c) ATF4-deficient dopaminergic neurons 338 are protected in cellular PD models, and importantly that (d) pharmacological inhibition of ATF4 339 attenuates neuronal loss in PD paradigms. 340 341 ATF4 is known to induce the expression of genes involved mitigating cellular stresses but during 342 prolonged activation is also known to induce the expression of pro-apoptotic factors (Harding et 343 al., 2003; Zinszner et al., 1998) . Therefore, it is not surprising that ATF4 has been reported to vivo. In contrast, it has been reported that in PC12 cells ATF4 expression induces Parkin 356 expression and promotes cell survival in PD toxin paradigms (Sun et al., 2013) . However, a more recent study by this group demonstrated that the ATF4 target Trib3 is induced in cellular models 358 of PD and promotes neuronal death by decreasing Parkin levels in neurons (Aimé et al., 2015) . 359
Although our results demonstrate that ATF4 is a key regulator of neuronal death in cellular 360 models of PD, future studies will be needed to evaluate the role of ATF4 in in vivo models of PD. 361
However, this will require the generation of brain specific conditional knockout models as adult 362 ATF4 germline knockout mice exhibit peripheral phenotypes including decreased bone mass and 363 microphthalmia (defect in eye lens formation that renders them essentially blind) and thus are 364 reported that PERK signalling is elevated in PD brains and in the SNpc of rodents treated with 6-395
OHDA (Mercado et al., 2018b) . Furthermore, they demonstrated that administration of the PERK 396 inhibitor GSK2606414 protected nigrostriatal neurons against 6-OHDA induced toxicity and 397 improved motor function. In this study we found that the PKR inhibitor C16 reduced ATF4 398 induction and ATF4 mediated transcriptional induction of the pro-apoptotic targets Chop and 399
Trib3. Furthermore, we found that C16 markedly reduced MPP+ and 6-OHDA induced 400 dopaminergic neuron death in mesencephalic cultures. Interestingly, we found that C16 also 401 attenuated ATF4 activation by oxidative stressors and the classic ER stressor thapsigargin. ER 402 stress is generally thought to activate ATF4 via the PERK pathway suggesting that C16 may be 403 able to inhibit PERK in addition to PKR. However, we can also not rule out the possibility that C16 404 may be affecting ATF4 activation via an off-target mechanism. Indeed, it has previously been 405
reported that C16 can also exert neuroprotection via PKR-independent mechanisms possibly 406 involving inhibition of CDK5 (Chen, Wang, & D'Mello, 2008) . Considering this, further studies 407 should aim to better understand the mechanism by which C16 exerts its neuroprotective effects 408 and how this compound may contribute to a reduction in ATF4-induced neuronal cell death. 
